Sample Size Determination for Number of Patient Interviews When Developing a PRO Using Qualitative Research Based on the 2009 FDA PRO Guidance

Similar documents
Study Endpoint Considerations: Final PRO Guidance and Beyond

Donald L. Patrick PhD, MSPH, Laurie B. Burke RPh, MPH, Chad J. Gwaltney PhD, Nancy Kline Leidy PhD, Mona L. Martin RN, MPA, Lena Ring PhD

Task Force Background Donald Patrick. Appreciation to Reviewers. ISPOR PRO GRP Task Force Reports

Patient-Reported Outcomes (PROs) and the Food and Drug Administration Draft Guidance. Donald L. Patrick University of Washington

SAMPLE SIZE, GROUNDED THEORY, AND SATURATION IN COA DEVELOPMENT. Guidance for Industry: Sample size

Chapter 1. Introduction

Quantifying the clinical measure of interest in the presence of missing data:

Addressing Content Validity of PRO Measures: The Unique Case of Rare Diseases

Ken Bridges, MD Global Blood Therapeutics, South San Francisco, CA

Patient Reported Outcomes (PROs) Tools for Measurement of Health Related Quality of Life

Funnelling Used to describe a process of narrowing down of focus within a literature review. So, the writer begins with a broad discussion providing b

Considerations for requiring subjects to provide a response to electronic patient-reported outcome instruments

INTERVIEWS II: THEORIES AND TECHNIQUES 5. CLINICAL APPROACH TO INTERVIEWING PART 1

Quantitative Approaches for Estimating Sample Size for Qualitative Research in COA Development and Validation

A Comparison of Variance Estimates for Schools and Students Using Taylor Series and Replicate Weighting

School of Population and Public Health SPPH 503 Epidemiologic methods II January to April 2019

USE OF ACCELEROMETER DATA TO EVALUATE PHYSICAL ACTIVITY AS A SURROGATE ENDPOINT IN HEART FAILURE CLINICAL TRIALS. Tracy Bergemann PhD

Statistical Analysis Plans

Benefit - Risk Analysis for Oncology Clinical Trials

Evidence Based Medicine

in alphabetical order:

Answers to end of chapter questions

Testing the measurement equivalence of electronically migrated patient-reported outcome (PRO) instruments: Challenges and Solutions

Missing Data in Longitudinal Studies: Strategies for Bayesian Modeling, Sensitivity Analysis, and Causal Inference

CHAPTER 3 RESEARCH METHODOLOGY

Health Economics & Decision Science (HEDS) Discussion Paper Series

ZERO SUICIDE DATA ELEMENTS WORKSHEET

BACKGROUND + GENERAL COMMENTS

Estimating sample size for qualitative research in clinical outcome assessment research: one size does not fit all! IP23

Combining Risks from Several Tumors Using Markov Chain Monte Carlo

Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient

Re: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion

Update on CDER s Drug Development Tool Qualification Program

ST440/550: Applied Bayesian Statistics. (10) Frequentist Properties of Bayesian Methods

Quantitative challenges of extrapolation

CDISC - Mapping New Pathways for Novartis. Darren Weston, Project Leader Pat Majcher, Senior Principal Programmer

Overview of EPA s Approach for Indirect Dietary Exposure Assessment of Residential and Commercial Food Contact Antimicrobial Products

PRECEDE-PROCEED PRECEDE-PROCEED

Public Health Masters (MPH) Competencies and Coursework by Major

Clinical Trials A Practical Guide to Design, Analysis, and Reporting

METHODOLOGIES FOR INTERMITTENT AND SHORT-TERM EXPOSURE TO CARCINOGENS SUBCOMMITTEE

Evolving Cervical Cancer Screening Options in Clinical Practice

Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) Additional considerations for cross-over trials

WATCHMAN PROTECT AF Study Rev. 6

Background Comparative effectiveness of ibrutinib

What is a Special Interest Group (SIG)?

Educational Research

CSC2130: Empirical Research Methods for Software Engineering

Clinician-reported Outcomes (ClinROs), Concepts and Development

Evolution of Occupational Therapy Practice: Life History of Nancy Rentfrow

Propensity Score Methods for Estimating Causality in the Absence of Random Assignment: Applications for Child Care Policy Research

Real-world observational data in costeffectiveness analyses: Herceptin as a case study

EPSE 594: Meta-Analysis: Quantitative Research Synthesis

Assessing and Managing Health Risks from Chemical Constituents and Contaminants of Food

Special thanks to: United States Environmental Protection Agency, as well as the 2017 Nutrient Permitting Workshop Planning Committee

Lec 02: Estimation & Hypothesis Testing in Animal Ecology

BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS

Quality of Life Instrument Development in Adults. American Cochlear Implant Alliance /8/18

Implementation of estimands in Novo Nordisk

Approaches to Integrating Evidence From Animal and Human Studies in Chemical Assessments

Kelvin Chan Feb 10, 2015

Background to the Task Force. Introduction

Model Disciplinary Guidelines

Rating Mental Impairment with AMA Guides 6 th edition:

The Role of Simulation in Assessing Extrapolation Assumptions

FORUM: QUALITATIVE SOCIAL RESEARCH SOZIALFORSCHUNG

John Quigley, Tim Bedford, Lesley Walls Department of Management Science, University of Strathclyde, Glasgow

Expert Elicitation on the Relative Risks of Processed Meat and Poultry Products

Scoring the Mood Screener and the CES-D. Ricardo F. Muñoz, Ph.D. University of California, San Francisco/San Francisco General Hospital

Quantitative Data Analysis (Using SPSS) Albard Khan, M.Ed Saturday, 7 November 2015

1, 2, 3-Trichloropropane (TCP): Assessment of Risks from Drinking Water

Country Participation: An Overview for Interested Investigators

Patient-Reported Outcomes to Support Medical Product Labeling Claims: FDA Perspective

The questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs

Research Design. Source: John W. Creswell RESEARCH DESIGN. Qualitative, Quantitative, and Mixed Methods Approaches Third Edition

6.3.5 Uncertainty Assessment

Controversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)

Innovative Analytic Approaches in the Context of a Global Pediatric IBD Drug Development

Statistical Audit. Summary. Conceptual and. framework. MICHAELA SAISANA and ANDREA SALTELLI European Commission Joint Research Centre (Ispra, Italy)

Clinical Trial Endpoints from Mobile Technology: Regulatory Considerations September 29, 2016

How has acceptability of healthcare interventions been defined and assessed? An overview of Systematic Reviews

ICH M4E(R2): Revised Guideline on Common Technical Document -- Efficacy

MIETTINEN OS: ON EXCELLENCE OF EPIDEMIOLOGIC ACADEMIA

FINAL. Recommendations for Update to Arsenic Soil CTL Computation. Methodology Focus Group. Contaminated Soils Forum. Prepared by:

Broad and clinically important benefits beyond the initial registrational endpoints are now reported.

Chapter 1 Data Types and Data Collection. Brian Habing Department of Statistics University of South Carolina. Outline

Making the Best of Imperfect Data: Reflections on an Ideal World. Mike Ambinder, PhD CHI PLAY 2014 October 20 th, 2014

Study Overview and Methods

Quality and Reporting Characteristics of Network Meta-analyses: A Scoping Review

Karin Hannes Methodology of Educational Sciences Research Centre KU Leuven

A CASE STUDY OF VALUE OF INFORMATION

Invalid rates workshop

Inductive Theory Building. June Cotte R.A. Barford Professor of

Northwestern University Institutional Review Board (IRB)

7TH ANNUAL AQC GLOBAL QUALITY SUMMIT SPONSORSHIP OPPORTUNITIES

Jake Bowers Wednesdays, 2-4pm 6648 Haven Hall ( ) CPS Phone is

Qualitative Research

5/10/2010. ISPOR Good Research Practices for Comparative Effectiveness Research: Indirect Treatment Comparisons Task Force

Assessing Consumer Responses to RRP: Experience at PMI in Developing Fit-for-Purpose Self-Report Instruments

Design and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies

Transcription:

Sample Size Determination for Number of Patient Interviews When Developing a PRO Using Qualitative Research Based on the 2009 FDA PRO Guidance Professor Consultant 2018 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop Washington D.C. September 12-14.

Excerpt from FDA PRO Guidance on Sample Size (# of Interviews).. We cannot provide recommendations for the number or size of the individual patient interviews or focus groups for establishing content validity. The sample size depends on the completeness of the information obtained from analysis of the transcripts. Generally, the number of patients is not as critical as interview quality and patient diversity included in the sample in relation to intended clinical trial population characteristics. Today: terminology sample size I mean: Number of interviews, 9/19/2018 (6)

Today Define Type I error in interviews for PRO development Statistical /probability based definition of saturation A worked example with published data Sample size considerations 1. Classical statistical Methods 2. Capture- Recapture (CRC) framework 3. On-going- Bayesian CRC Roadblocks availability of interview datasets in public domain 9/19/2018 (4)

Today: Miscellaneous jargon interviews for a PRO result in codes or concepts An instrument such as the SF-36 to arise from at least 36 codes or 36 concepts

The Background 9/19/2018 Teleconference CEO, CMO, Clinops,a (never-to-be-named) PRO vendor V:, and CB (me!) CEO: How many more interviews? Vendor: as soon as we achieve saturation CEO: What is saturation? V: zero new codes CB: do interviews stop at first occurrence of 0 or maybe a couple more for possible statistical noise? V: No CB: and how many codes expected? V: We Don t Know CB: how do we know its not a Type I error? Prominent PRO expert explains agency frequently asks for more interviews (2)

Literature Review: Saturation and Sample Size (number of interviews) Define saturation as zero new concepts a.k.a. First interview with saturation Three consecutive interviews with zero new codes Expert Judgement additional interviews would be counter productive SAMPLE SIZE Ethnography/ethnoscience 30-60 interviews Grounded Theory 30-50 interviews Phenomenology 5-25 interviews All Qualitative research at least 15 interviews Funded ($) research time limited interviews ranged from 1 95 ETC. There do not appear to be formal statistical methods for sample size or saturation 9/19/2018 (5)

Conceptual overview of coding in qualitative research

ROADBLOCKS to PRO interview Sample size Research 1. interview datasets for PRO development not routinely published or in public domain 2.Data set today from a literature search Guest, Bunce. 1. Original interview level data not available per Dr. Guest 9/19/2018 Chris Barker Www.barkerstats.com 8

Guest, Bunce- Figure I Interviews in groups of 6. Interview level data not available 6 interviews 5 codes 6 interviews 0 codes 6 interviews 1 codes 9/19/2018 9

9/19/2018 Key assumptions of my methodology Before interviewing a fixed- and unknown total number of codes One interview per subject (patient ) Interviews in chronological order First interview elicits new codes Second and later interviews elicit a mix of new or previously reported codes Number of new codes eventually declines to zero Interview with 0 new codes may and must- occur more than once. No Hypothesis test/no p-values. Use all data. (9)

For Today Only I selected a Kaplan Meier Non-parametric Estimator Pragmatic choice The methodology can be generalized using other survival type distributions (exponential, etc.) Generalizing requires an interview/patient level dataset.

Preparing a dataset from Guest et al. to exhibit a model Impute one or more interviews of 6 with 0 new codes when total codes from block of 6 is <6. Prefer to have interview level data

Note: data extracted from Guest Figure I 100% Probability of not being saturated 9/19/2018 13-18 Possible Type I error 0% Probability of not being saturated Upper 95% C.I. Probability of not being saturation 13

Saturation Type I Error truth table Interview Assessment Saturation Not Saturation Type I Truth Saturation Not Saturation Type II

Direct Sample Size Estimation Initial classical single group time to event methods, median, mean, 50 th -tile interim or indirect methods using capture recapture Simulation based Research underway Bayesian CRC methods suitable for small samples

Indirect sample size estimates using Capture Recapture a.k.a Lincoln Peterson Capture Recapture (CRC) wide and diverse- use, for estimating wildlife populations ( # bears in Yellowstone park ), software bugs, human rights violations, aka. For PRO development used as interviews are conducted for an INDIRECT method of estimating total number of interviews (sample size). I am NOT proposing to use CRC for estimating total number of codes Several CRC estimators.

brief review: Capture recapture (CapRec) For indirect sample size estimation, NOT for definitive estimate of number of codes. Simplest case. Population of bears in Yellowstone Randomly sample bears. Tag(mark) bears, release into wild Second random sample, count number of marked vs. unmarked bears. Estimators use counts of total sample, marked and unmarked to estimate total number of bears with confidence interval For PRO s we are sampling codes

Indirect sample size estimates using Capture Recapture (CRC) I was privately provided with an anonymized data set of interview information in a matrix format. Columns are anonymized codes, rows are interviews in chronological order, I used several CRC estimators, Lincoln Peterson, other extensions. I estimated total new codes at each interview All estimators and their upper confidence limit UNDERESTIMATE the total new codes. Underestimation is a known- problem with CRC estimators

Example of Static PRO interview Matrix at the end of all interviews with 0/1 codes 1=code found 0= not found Interview Number Anonymized CODE /concept A B C D E F ZZ 1 1 1 1 1 1 1 1 1 2 0 0 1 0 0 1 1 0 3 1 1 1 1 0 0 0 0 k

Bayesian Capture Recapture for small samples a.k.a small number of codes The full Capture Recapture matrix evolves by interview

Formal Sample Size Algorithms to appear in publication I. Initial Estimate of N of interviews, ballpark of number of codes II. Revised estimate of number of codes as often as 2 nd and later interviews using capture recapture III. Estimate of probability of saturation IV. If needed Extrapolate probability of saturation to estimate total number of interviews with upper confidence interval V. Use classical sample size for time to VI. Indirect estimate of sample size - Estimate number of codes at each interview > 2, by capture recapture 9/19/2018 (12)

Conclusions Define Type I error for saturation Initial Estimate of number of interviews (sample size) Estimate saturation probability (0.0%) and C.I. indirect assessment of sample size by estimating number of codes (capture recapture) Dataset structure required for analysis (add to STDM / ADaM?) Formal Methods intended to be acceptable in a regulatory setting 9/19/2018 (13)

Questions

References Brédart, Anne, et al. "Interviewing to develop Patient-Reported Outcome (PRO) measures for clinical research: eliciting patients experience." Health and quality of life outcomes 12.1 (2014): 15. Francis, Jill J., et al. "What is an adequate sample size? Operationalising data saturation for theory-based interview studies." Psychology and Health25.10 (2010): 1229-1245. Fusch, Patricia I., and Lawrence R. Ness. "Are we there yet? Data saturation in qualitative research." The Qualitative Report 20.9 (2015): 1408. Mason, Mark. "Sample size and saturation in PhD studies using qualitative interviews." Forum qualitative Sozialforschung/Forum: qualitative social research. Vol. 11. No. 3. 2010. Patrick, Donald L., et al. "Content validity establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1 eliciting concepts for a new PRO instrument." Value in Health 14.8 (2011): 967-977. Patrick, Donald L., et al. "Content validity establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2 assessing respondent understanding." Value in Health14.8 (2011): 978-988. Wasserstein, Lazar The ASA's statement on p-values: context, process, and purpose, The American Statistician, 2016 9/19/2018 (15)

Thank you